Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kerry, D. W.
Right arrow Articles by Brumfitt, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerry, D. W.
Right arrow Articles by Brumfitt, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1975) 1, 417-427
© 1975 The British Society for Antimicrobial Chemotherapy

other

Trimethoprim and rifampicin: in vitro activities separately and in combination

D. W. Kerry, J. M. T. Hamilton-Miller and W. Brumfitt

Department of Medical Microbiology The Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, England

accepted 30 July 1975

Rifarnpicin and trimethoprirn, acting alone, showed high antibacterial activity and broad spectra against 386 strains taken from 9 genera (15 species) of common hospital pathogens. When tested in combination against 304 of these strains, using a method that allows quantitative analysis of the interaction, synergism or addition was almost always observed. The best synergistic action was against streptococci and strains of Proteus spp. The effect was also synergistic or additive against all strains of Kiebsielia aerogenes, Escherichia coli, Enterobacter spp., Pseudonwnas aeruginosa, Bacteroides fragilis and Salmonella typhlmurium which were tested. Only in the case of Staphylococcus aureus was some antagonism observed, but this occurred only at very low concentrations of rifampicin.

In the presence of sub-inhibitory levels of trimethoprim the incidence of rifampicin-resistant mutants was decreased.

In view of these extremely encouraging and consistent results, we regard the combination of rifampicin and trimethoprim as of sufficient potential to warrant further investigation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
J. Perlroth, M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller
Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature
Arch Intern Med, April 28, 2008; 168(8): 805 - 819.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
W. Brumfitt, M. R. J. Salton, and J. M. T. Hamilton-Miller
Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci
J. Antimicrob. Chemother., November 1, 2002; 50(5): 731 - 734.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
G. P. WORMSER and G. T. KEUSCH
Drugs Five Years Later: Trimethoprim-Sulfamethoxazole in the United States
Ann Intern Med, September 1, 1979; 91(3): 420 - 429.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.